Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk
Boston Scientific recalls Infinion CX SCS leads following 1,081 injury reports. Health authorities urge immediate return of unused inventory.
Stocks · News reference
Boston Scientific Reports Global Disruption After Cybersecurity Incident
Boston Scientific reports a cyber incident disrupting global operations, limiting system access and affecting order processing and shipments.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)
The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.
Boston Scientific shares are trading lower after the FDA disclosed it is aware that the companyissued a letter to affected customers recommending all unused Infinion CX Leads be removed from where they are used or sold.
FDA Says Aware Boston Scientific Issued Letter To Affected Customers Recommending Unused Infinion CX Leads Be Removed From Where They Are Used/Sold; As Of May 27, 2026, Boston Scientific Reported 1,081 Serious Injuries And No Deaths Associated With Issue Related To Infinion CX Leads
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.